Tagged with R

GlaxoSmithKline pharmaceuticals S.A. In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your entire professional career to GlaxoSmithKline (GSK), that you joined in 1992. What has kept you within the group, what has…

polski holding farmaceutyczny (PHF) Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was to privatise the three entities. You joined in March 2008, at a time when, if I may say, major steps…

Servier Brasil When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be? Actually, these projections turned out to be quite conservative. In the last two years Servier has doubled its Brazilian revenues…

Novartis Argentina When we met with Javier Lombar at IMS Argentina, he was explaining how a lot of multinational companies are using Argentina as a regional base of operations. Novartis is a prime example of this. Could you explain how Novartis operates in a Latin American context, and what role the Argentinean…

INFARMA Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and become an attractive market for innovators. Could you give us an idea of how the market for innovative drugs has…

Roemmers Roemmers fue establecida en 1921. ¿Cómo paso de ser una empresa familiar a la empresa que es hoy, y cuáles han sido los desafíos en el cambio en la cultura de la empresa? La crisis económica que sufrió Argentina en 2002, sirvió como catalizador para un cambio radical en Roemmers,…

Octapharma Brazil Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could you delve a bit deeper and elaborate on this point? Before delving into the Brazilian market situation, it is important…

Česká asociace farmaceutických firem (ČAFF) Dr. Zörner, can you please begin by introducing our readers to the CAFF (Czech Association of Pharmaceutical Firms), and explicate its key activities and mission? We represent 24 companies in the Czech pharmaceutical industry that are mainly involved in the generics business. Our mission is to promote the generics industry,…

State Institute for Drug Control (SUKL) Mr. Březovký, can you begin with an introduction to SUKL and its role within the Czech Republic’s complex regulatory environment? I would like to begin by noting that I have been at my position as director of SUKL from the 1st of May of this year—today, I have been six…

BOIRON Czech Republic In the Czech Republic, homeopathic medicines were prohibited during the communistic period, but found resurgence after 1989. Can you give us an overview of the development of this form of treatment in the Czech market, and speak about the role that BOIRON has had in the evolution of the segment?…

Pharmaceutical Manufacturers Association of Turkey (IEIS) IEIS is an association with dual responsibilities. Promotion of generic usage in turkey and ensuring the sustained development of a local manufacturing industry. Before we look into these two aspects, I would like you to give us your perspective on the future role of the association, in an environment where…

AstraZeneca Turkey Even though you have delivered strong results in most of the markets you have been appointed, this is your first assignment as the head of a subsidiary. For a man and manager who has experienced only successes in his life and career, what were the new challenges of leading a…